Highlight
KRAS mutations, especially non-G12C subtypes, represent a significant challenge in NSCLC targeted therapy due to limited effective options.
MEK inhibitor trametinib induces adaptive resistance via feedback activation of multiple receptor tyrosine kinases (RTKs).
Specialty calculators
For clinical reference; use professional judgment.
